clinical trial · NCT04629547
Sleep Trial to Prevent Alzheimer's Disease
SleepAlzheimer DiseaseSuvorexant 20 mgPlacebo
brief summary
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
started
May 25, 2022
primary completion
May 1, 2028
completion
May 1, 2028
last updated
Jun 30, 2026
detailed description
This study will investigate if long-term treatment with suvorexant will slow amyloid-β accumulation in the brain. Amyloid-β is a protein involved in the disease process leading to Alzheimer's disease. This study will evaluate if suvorexant can decrease the amount of amyloid-beta detected by plasma pT217/T217.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol